Cargando…

Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study

OBJECTIVE: To evaluate enzymatic total serum bile acid quantification as a monitoring strategy for women with intrahepatic cholestasis of pregnancy (ICP) treated with ursodeoxycholic acid (UDCA). DESIGN: Cohort. SETTING: One UK university hospital. POPULATION: 29 ICP cases treated with UDCA. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Manna, LB, Ovadia, C, Lövgren‐Sandblom, A, Chambers, J, Begum, S, Seed, P, Walker, I, Chappell, LC, Marschall, H‐U, Williamson, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899621/
https://www.ncbi.nlm.nih.gov/pubmed/31483939
http://dx.doi.org/10.1111/1471-0528.15926
_version_ 1783477170909216768
author Manna, LB
Ovadia, C
Lövgren‐Sandblom, A
Chambers, J
Begum, S
Seed, P
Walker, I
Chappell, LC
Marschall, H‐U
Williamson, C
author_facet Manna, LB
Ovadia, C
Lövgren‐Sandblom, A
Chambers, J
Begum, S
Seed, P
Walker, I
Chappell, LC
Marschall, H‐U
Williamson, C
author_sort Manna, LB
collection PubMed
description OBJECTIVE: To evaluate enzymatic total serum bile acid quantification as a monitoring strategy for women with intrahepatic cholestasis of pregnancy (ICP) treated with ursodeoxycholic acid (UDCA). DESIGN: Cohort. SETTING: One UK university hospital. POPULATION: 29 ICP cases treated with UDCA. METHODS: Serial samples were collected prospectively throughout gestation. Total serum bile acids were measured enzymatically and individual bile acids by high‐performance liquid chromatography‐tandem mass spectrometry. Data were log‐transformed and analysed with random effects generalised least square regression. MAIN OUTCOME MEASURES: The relationship between enzymatic total bile acid measurements and individual bile acid concentrations after UDCA treatment. RESULTS: In untreated women, cholic acid was the principal bile acid (51%) and UDCA concentrations were <0.5%, whereas UDCA constituted 60% (IQR 43–69) of serum bile acids following treatment and cholic acid fell to <20%. Changes in the total bile acid measurement reflected similar alterations in the concentrations of the pathologically elevated bile acids, e.g. a two‐fold increase in enzymatic total bile acids is accompanied by approximately a two‐fold increase in cholic acid and chenodeoxycholic acid at most UDCA doses (P < 0.001). Most of the effects of UDCA on cholic acid occur in the first week of treatment (60% relative reduction, P = 0.025, 95% CI 0.2–0.9, from 10 micromol/l (4.7–17.6) to 3.5 micromol/l (1.4–7.5). CONCLUSION: Ursodeoxycholic acid becomes the main component of the bile acid measurement after treatment. Enzymatic total bile acid assays are good predictors of both cholic acid and chenodeoxycholic acid, the primary bile acids that are raised prior to treatment. TWEETABLE ABSTRACT: Ursodeoxycholic acid constitutes approximately 60% of the bile acid measurement and reduces pathological cholic acid in treated women.
format Online
Article
Text
id pubmed-6899621
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68996212019-12-19 Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study Manna, LB Ovadia, C Lövgren‐Sandblom, A Chambers, J Begum, S Seed, P Walker, I Chappell, LC Marschall, H‐U Williamson, C BJOG Maternal Medicine OBJECTIVE: To evaluate enzymatic total serum bile acid quantification as a monitoring strategy for women with intrahepatic cholestasis of pregnancy (ICP) treated with ursodeoxycholic acid (UDCA). DESIGN: Cohort. SETTING: One UK university hospital. POPULATION: 29 ICP cases treated with UDCA. METHODS: Serial samples were collected prospectively throughout gestation. Total serum bile acids were measured enzymatically and individual bile acids by high‐performance liquid chromatography‐tandem mass spectrometry. Data were log‐transformed and analysed with random effects generalised least square regression. MAIN OUTCOME MEASURES: The relationship between enzymatic total bile acid measurements and individual bile acid concentrations after UDCA treatment. RESULTS: In untreated women, cholic acid was the principal bile acid (51%) and UDCA concentrations were <0.5%, whereas UDCA constituted 60% (IQR 43–69) of serum bile acids following treatment and cholic acid fell to <20%. Changes in the total bile acid measurement reflected similar alterations in the concentrations of the pathologically elevated bile acids, e.g. a two‐fold increase in enzymatic total bile acids is accompanied by approximately a two‐fold increase in cholic acid and chenodeoxycholic acid at most UDCA doses (P < 0.001). Most of the effects of UDCA on cholic acid occur in the first week of treatment (60% relative reduction, P = 0.025, 95% CI 0.2–0.9, from 10 micromol/l (4.7–17.6) to 3.5 micromol/l (1.4–7.5). CONCLUSION: Ursodeoxycholic acid becomes the main component of the bile acid measurement after treatment. Enzymatic total bile acid assays are good predictors of both cholic acid and chenodeoxycholic acid, the primary bile acids that are raised prior to treatment. TWEETABLE ABSTRACT: Ursodeoxycholic acid constitutes approximately 60% of the bile acid measurement and reduces pathological cholic acid in treated women. John Wiley and Sons Inc. 2019-09-26 2019-12 /pmc/articles/PMC6899621/ /pubmed/31483939 http://dx.doi.org/10.1111/1471-0528.15926 Text en © 2019 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Maternal Medicine
Manna, LB
Ovadia, C
Lövgren‐Sandblom, A
Chambers, J
Begum, S
Seed, P
Walker, I
Chappell, LC
Marschall, H‐U
Williamson, C
Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study
title Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study
title_full Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study
title_fullStr Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study
title_full_unstemmed Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study
title_short Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study
title_sort enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study
topic Maternal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899621/
https://www.ncbi.nlm.nih.gov/pubmed/31483939
http://dx.doi.org/10.1111/1471-0528.15926
work_keys_str_mv AT mannalb enzymaticquantificationoftotalserumbileacidsasamonitoringstrategyforwomenwithintrahepaticcholestasisofpregnancyreceivingursodeoxycholicacidtreatmentacohortstudy
AT ovadiac enzymaticquantificationoftotalserumbileacidsasamonitoringstrategyforwomenwithintrahepaticcholestasisofpregnancyreceivingursodeoxycholicacidtreatmentacohortstudy
AT lovgrensandbloma enzymaticquantificationoftotalserumbileacidsasamonitoringstrategyforwomenwithintrahepaticcholestasisofpregnancyreceivingursodeoxycholicacidtreatmentacohortstudy
AT chambersj enzymaticquantificationoftotalserumbileacidsasamonitoringstrategyforwomenwithintrahepaticcholestasisofpregnancyreceivingursodeoxycholicacidtreatmentacohortstudy
AT begums enzymaticquantificationoftotalserumbileacidsasamonitoringstrategyforwomenwithintrahepaticcholestasisofpregnancyreceivingursodeoxycholicacidtreatmentacohortstudy
AT seedp enzymaticquantificationoftotalserumbileacidsasamonitoringstrategyforwomenwithintrahepaticcholestasisofpregnancyreceivingursodeoxycholicacidtreatmentacohortstudy
AT walkeri enzymaticquantificationoftotalserumbileacidsasamonitoringstrategyforwomenwithintrahepaticcholestasisofpregnancyreceivingursodeoxycholicacidtreatmentacohortstudy
AT chappelllc enzymaticquantificationoftotalserumbileacidsasamonitoringstrategyforwomenwithintrahepaticcholestasisofpregnancyreceivingursodeoxycholicacidtreatmentacohortstudy
AT marschallhu enzymaticquantificationoftotalserumbileacidsasamonitoringstrategyforwomenwithintrahepaticcholestasisofpregnancyreceivingursodeoxycholicacidtreatmentacohortstudy
AT williamsonc enzymaticquantificationoftotalserumbileacidsasamonitoringstrategyforwomenwithintrahepaticcholestasisofpregnancyreceivingursodeoxycholicacidtreatmentacohortstudy